Clinical Observation on Telbivudine Tablets Combined with Dangfei Liganning Capsule（当飞利肝宁胶囊） in the Treatment of 30 Cases of Chronic Hepatitis B with HBeAg Positive

SHEN Jianjun

doi:10.13288/j.11-2166/r.2015.22.016

您当前的位置：

首页 >

文章列表页 >

Clinical Observation on Telbivudine Tablets Combined with Dangfei Liganning Capsule（当飞利肝宁胶囊） in the Treatment of 30 Cases of Chronic Hepatitis B with HBeAg Positive

更新时间：2021-11-17

- Clinical Observation on Telbivudine Tablets Combined with Dangfei Liganning Capsule（当飞利肝宁胶囊） in the Treatment of 30 Cases of Chronic Hepatitis B with HBeAg Positive
- Journal of Traditional Chinese Medicine Vol. 56, Issue 22, Pages: 1946-1948(2015)
- 作者机构：
  
  东南大学附属第二医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2015.22.016
  CLC： R512.62
- Published：2015
- 稿件说明：
移动端阅览
[1]沈建军.替比夫定片联合当飞利肝宁胶囊治疗E抗原阳性慢性乙型肝炎患者30例临床观察[J].中医杂志,2015,56(22):1946-1948.

SHEN Jianjun. Clinical Observation on Telbivudine Tablets Combined with Dangfei Liganning Capsule（当飞利肝宁胶囊） in the Treatment of 30 Cases of Chronic Hepatitis B with HBeAg Positive[J]. Journal of Traditional Chinese Medicine2015, 56(22): 1946-1948.
[1]沈建军.替比夫定片联合当飞利肝宁胶囊治疗E抗原阳性慢性乙型肝炎患者30例临床观察[J].中医杂志,2015,56(22):1946-1948. DOI： 10.13288/j.11-2166/r.2015.22.016.

SHEN Jianjun. Clinical Observation on Telbivudine Tablets Combined with Dangfei Liganning Capsule（当飞利肝宁胶囊） in the Treatment of 30 Cases of Chronic Hepatitis B with HBeAg Positive[J]. Journal of Traditional Chinese Medicine2015, 56(22): 1946-1948. DOI： 10.13288/j.11-2166/r.2015.22.016.

摘要

目的观察替比夫定片联合当飞利肝宁胶囊治疗E抗原阳性慢性乙型肝炎患者的临床疗效。方法将60例E抗原阳性慢性乙型肝炎患者随机分为治疗组和对照组各30例。对照组给予替比夫定片

每次600 mg

每日1次

口服;治疗组在对照组基础上给予当飞利肝宁胶囊

每次1.0 g

每日3次

口服。分别在治疗前及治疗后12周、24周时观察两组患者HBV DNA定量、肝功能[包括总胆红素（TBiL）、丙氨酸氨基氨基转移酶（ALT）、门冬氨酸氨基转移酶（AST）]、肝纤维化指标[包括血清透明质酸（HA）、层粘蛋白（LN）、Ⅲ型前胶原（PC-Ⅲ）、Ⅳ型胶原（CL-Ⅳ）]、肝脏瞬时弹性的改变。结果治疗后12周及24周两组患者HBV DNA定量、肝功能、肝脏瞬时弹性及HA、LN、PC-Ⅲ、CL-Ⅳ水平均较治疗前下降（P<0.05）。治疗后24周与12周比较

两组患者HBV DNA定量、肝功能、肝脏瞬时弹性及HA、LN、PC-Ⅲ、CL-Ⅳ水平亦明显下降（P<0.05）。两组患者治疗后12周及24周HBV DNA定量和肝功能组间比较差异均无统计学意义（P>0.05）。治疗组肝脏瞬时弹性和HA、LN、PC-Ⅲ、CL-Ⅳ水平治疗后12周及24周时较对照组明显下降（P<0.05）。结论替比夫定片联合当飞利肝宁胶囊治疗E抗原阳性慢性乙型肝炎患者

不仅可以有效改善肝功能指标

控制HBV DNA水平

同时明显改善肝脏纤维化和肝脏瞬时弹性

延缓疾病进展。

Abstract

Objective To observe the clinical efficacy of Telbivudine tablets combined with Dangfei Liganning Capsule in the treatment of chronic hepatitis B patients with HBe Ag positive. Methods Totally 60 cases of chronic hepatitis B with HBe Ag positive were randomly divided into a treatment group and a control group

with 30 cases in each group. Both groups were given Telbivudine Tablets orally

600 mg each time

once daily. The treatment group was added with Dangfei Liganning Capsule orally

1.0g each time

once daily. Changes in DNA HBV quantification

liver function index [including total bilirubin（ TBiL）

alanine amino transferase（ ALT）

and aspartate aminotransferase（ AST） ]

hepatic fibrosis index [including serum hyaluronic acid（ HA）

laminin（ LN）

type III collagen（ PC-Ⅲ）

and type Ⅳ collagen（ CL-Ⅳ） ]and transient liver elasticity were observed in both groups before and 12 weeks and 24 weeks after treatment. Results DNA HBV quantification

liver function index

transient liver elasticity

and levels of HA

PC-Ⅲ

and CL-Ⅳ were decreased in both groups 12 weeks and 24 weeks after treatment（ P<0. 05）. Comparison between 24 weeks and 12 weeks after treatment showed DNA HBV quantification

liver function index

transient liver elasticity

and levels of HA

PC-Ⅲ

and CL-Ⅳ in both groups also decreased significantly 24 weeks after treatment compared with those 12 weeks after treatment（ P<0. 05）. There were no significant differences in DNA HBV quantitative and liver function index between the two groups（ P>0. 05）. The transient liver elasticity and levels of HA

PC-Ⅲ

and CL-Ⅳ were significantly decreased in the treatment group compared with those in the control group 12 and 24 weeks after treatment（ P<0. 05）. Conclusion In the treatment of chronic hepatitis B patients with HBe Ag positive

telbivudine tablets combined with Dangfei Liganning Capsule can not only effectively improve the liver function and control HBV DNA level

but also significantly improve liver fibrosis and liver transient elasticity

so that to delay the progress of the disease.

关键词

Keywords

references

查看原文

Views

115

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Observation on Right-Supporting Liver-Emolliating Formula Combined With Lamivudine for 30 Cases of Liver Fibrosis in Chronic Hepatitis B

Effect of Yinqi Sanhuang Jiedu Decoction （茵芪三黄解毒汤） on Macrophage Polarization and the Piezo1/PI3K/AKT Pathway in Liver Tissue of Liver Fibrosis Model Mice

Pathogenesis Characteristics and Progression Patterns of Liver Fibrosis in 644 Patients with Chronic Hepatitis B

The Effect of Fuzheng Huaji Formula （扶正化积方） for Chronic Hepatitis B on Reduction of the Incidence of Liver Cirrhosis and Hepatocellular Carcinoma：A Retrospective Cohort Study

Evolutionary Law of Syndrome and Syndrome Elements during the Malignant Transformation of Chronic Hepatitis B

Related Author

LIU Junhong

WANG Longde

WANG Min

MAO Lanfang

HUANG Bohao

WU Qingjuan

WANG Jiuchong

LI Yanbo

Related Institution

University Hospital of Gansu Traditional Chinese Medicine

Guizhou Province Hospital of Traditional Chinese Medicine

Gansu University of Traditional Chinese Medicine

Graduate School，Beijing University of Chinese Medicine

Guang 'anmen Hospital，China Academy of Chinese Medical Sciences

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰